Previous 10 | Next 10 |
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2019 Earnings Conference Call November 13, 2019 8:00 AM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Ferguson - Chief Medical Officer ...
Matinas Biopharma (NYSEMKT: MTNB ): Q3 GAAP EPS of -$0.03 in-line. More news on: Matinas BioPharma Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020 – – NIH-funded Phase 2 EnACT trial of MAT2203 in cryptococcal meningitis initiated in Oc...
BEDMINSTER, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Wednesday, November 13, 2019 at 8:00 a.m. ET to discuss op...
October 29, 2019 Palm Beach, FL – October 29, 2019 – There is much activity in the nanotechnology & nanomedicine markets as new treatments and human clinical trials are growing at a record pace. And these new treatment are hope they could be key to combating vi...
Introduction Matinas BioPharma ( MTNB ) is a small-cap ($116 million) clinical-stage company founded in 2013. It has a diverse pipeline with investigative drug candidates MAT2203 , MAT2501 , and MAT9001 in clinical development for leukemia, Mycobacterium Infections and hypertriglyceridem...
BEDMINSTER, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenanc...
BEDMINSTER, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MAT2203, Matinas’ proprietar...
BEDMINSTER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the 20...
BEDMINSTER, N.J., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to determine eligibility for ENHANCE-IT, its Phase 2 head-to-head pharmacodynamic...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...